Trial
NCT00746980
Efalizumab in the Treatment of Alopecia, Phase II
Phase IIWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
Northwestern University
Collaborators
Genentech, Inc.
Condition
Alopecia Totalis
Intervention
efalizumab
Why stopped
Newly identified safety concerns have changed the risk and benefit considerations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-14